C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/63 (2006.01) C12N 15/113 (2010.01) A61K 48/00 (2006.01) C07H 21/00 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2755409
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF2.
La présente invention concerne des oligonucléotides antisens qui modulent l'expression et/ou la fonction du facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (NRF2), en particulier, par ciblage de polynucléotides antisens naturels de facteur nucléaire 2 similaire au dérivé d'érythroïde 2 (NRF2). L'invention concerne en outre l'identification de ces oligonucléotides antisens et leur utilisation dans le traitement de maladies et troubles associés à l'expression de NRF2.
Coito Carlos
Collard Joseph
Khorkova Sherman Olga
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Opko Curna Llc
LandOfFree
Treatment of nuclear factor (erythroid-derived 2)-like 2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of nuclear factor (erythroid-derived 2)-like 2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of nuclear factor (erythroid-derived 2)-like 2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1904163